Нутритивная поддержка ооцитогенеза, овуляторных менструальных циклов витаминами фолатного цикла (витаминами В1, В6, В12, активной формой В9) и витамерами витамина В8 (Мио- и D-хироинозитол в соотношении 40:1) при предгравидарной подготовке

Роли фолатов (витамин В9) в формировании здоровых ооцитов (что важно для предупреждения пороков развития) хорошо известны. Для реализации физиологических эффектов фолатов необходимы и другие витамины группы В – витамины В1, В6, В12 и В8 (инозитолы). Миоинозитол (МИ) и D-хироинозитол (ДХИ) – два наиболее изученных инозитола, необходимых для поддержки ооцитов, восстановления овуляторных циклов и профилактики фолат-резистентных пороков. Обмен ДХИ и МИ нарушается на фоне инсулинорезистентности, в т.ч. у пациенток с ожирением и с синдромом поликистоза яичников (СПЯ). И наоборот, дотации пациенткам МИ и ДХИ в физиологическом соотношении 40:1 способствуют устранению инсулинорезистентности, гиперандрогении, ановуляции, препятствующих формированию здоровых ооцитов и, следовательно, зачатию.

1. Женское бесплодие. Клинические рекомендации РФ 2024 (Россия). Российское общество акушеров-гинекологов. 22.07.2024. https://diseases.medelement.com/disease/%D0%B6%D0%B5%D0%BD%D1%81%D0%BA%D0%BE%D0%B5-%D0%B1%D0%B5%D1%81%D0%BF%D0%BB%D0%BE%D0%B4%D0%B8%D0%B5-%D0%BA%D1%80-%D1%80%D1%84–2024/18106

2. Barati M, Nasehi N, Aberoumand S, Najafian M, Emami Moghadam A. Factors causing timely referral for fetal echocardiography in the final diagnosis of congenital heart malformations: A cross-sectional study. Int J Reprod Biomed. 2022 Jul 6; 20 (6): 477–482. https://doi.org/10.18502/ijrm.v20i6.11443

3. Finn J, Suhl J, Kancherla V, Conway KM, Oleson J, Sidhu A, Nestoridi E, Fisher SC, Rasmussen SA, Yang W, Romitti PA; National Birth Defects Prevention Study. Maternal cigarette smoking and alcohol consumption and congenital diaphragmatic hernia. Birth Defects Res. 2022 Aug 1; 114 (13): 746–758. https://doi.org/10.1002/bdr2.2059

4. Доброхотова Ю. Э., Джохадзе Л. С. Комплексная прегравидарная подготовка – реальный путь улучшения перинатальных исходов. Проблемы репродукции. 2019; 25 (6): 38–43. https://doi.org/10.17116/repro20192506138

5. Czeizel AE. Periconceptional folic acid–containing multivitamin supplementation. Eur J Obstet Gynec Reprod Biol. 1998; 75: 151–161.

6. Громова О.А., Торшин И.Ю., Иловайская И.А. Ооциты и холин-содержащие микронутриентные комплексы. Систематический анализ фармакологических эффектов. Вопросы гинекологии, акушерства и перинатологии. 2024; 23 (2): 61–72. https://doi.org/10.20953/1726-1678-2024-2-61-72

7. Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol. 2016; 2016: 1849162. DOI: 10.1155/2016/1849162. Epub 2016 Oct 23. PMID: 27843451.

8. Thomas MP, Mills SJ, Potter BV. The «Other» Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry). Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1614–50. DOI: 10.1002/anie.201502227. Epub 2015 Dec 22. PMID: 26694856.

9. Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002; 293 (3): 1092–1098.

10. Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002; 3 (1): 47–60. DOI: 10.1080/15604280212528. PMID: 11900279.

11. Громова О. А., Торшин И. Ю., Уварова Е. В., Тапильская Н. И., Калачева А. Г. Систематический анализ биологических ролей и фармакологических свойств D-хироинозитола. Гинекология. 2020; 22 (3): 21–28. DOI: 10.26442/20795696.2020.3.200210

12. Giménez-Bastida JA, Zieliński H. Buckwheat as a Functional Food and Its Effects on Health.J Agric Food Chem. 2015 Sep 16; 63 (36): 7896–913. DOI: 10.1021/acs.jafc.5b02498. Epub 2015 Sep 3. PMID: 26270637.

13. Громова О. А., Торшин И. Ю., Тетруашвили Н. К. Роли мио-инозитола в поддержании репродуктивного здоровья женщины. Повышение эффективности технологий экстракорпорального оплодотворения. РМЖ. Мать и дитя. 2018; 1 (1): 88–95. DOI: 10.32364/2618-8430-2018-1-1-88-95.

14. Торшин И. Ю., Громова О. А., Тетруашвили Н. К., Демидов В. И. Мио-инозитол: микронутриент для «тонкой настройки» женской репродуктивной сферы. РМЖ. Мать и дитя. 2018; 1 (2): 148–155. DOI: 10.32364/2618-8430-2018-1-2-148-155

15. Musacchio MC, Cappelli V, Di Sabatino A, Morgante G, De Leo V. Valutazione dell’associazione myo-inositolo-monacolina K sull’iperandrogenismo e sui parametri del metabolismo lipidico in donne con PCOS [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women]. Minerva Ginecol. 2013 Feb; 65 (1): 89–97. Italian. PMID: 23412023.

16. Corrado F, D’Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011 Aug; 28 (8): 972–5. DOI: 10.1111/j.1464–5491.2011.03284.x. PMID: 21414183.

17. Larner J. D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work.IUBMB Life. 2001 Mar; 51 (3): 139–48. DOI: 10.1080/152165401753544205. PMID: 11547915.

18. Whiting L, Danaher RN, Ruggiero K, Lee CC, Chaussade C, Mulvey T, Phillips A, Loomes KM. D-chiro-inositol attenuates epinephrine-stimulated hepatic glucose output in the isolated perfused liver independently of insulin. Horm Metab Res. 2013 May; 45 (5): 394–7. DOI: 10.1055/s-0032–1330016. Epub 2012 Dec 7. PMID: 23225249.

19. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2010 Apr; 8 (2): 127–36. DOI: 10.1089/met.2009.0052. PMID: 20156067; PMCID: PMC 3140116.

20. Ostlund RE Jr, Seemayer R, Gupta S, Kimmel R, Ostlund EL, Sherman WR. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3–3H]inositol. J Biol Chem. 1996 Apr 26; 271 (17): 10073–8. DOI: 10.1074/jbc.271.17.10073. PMID: 8626564.

21. Murphy A, Shamshirsaz A, Markovic D, Ostlund R, Koos B. Urinary Excretion of Myo-Inositol and D-Chiro-Inositol in Early Pregnancy Is Enhanced in Gravidas with Gestational Diabetes Mellitus.Reprod Sci. 2016 Mar; 23 (3): 365–71. DOI: 10.1177/1933719115602767. Epub 2015 Sep 8. PMID: 26355118.

22. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2010 Apr; 8 (2): 127–36. DOI: 10.1089/met.2009.0052. PMID: 20156067.

23. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002 Nov-Dec; 8 (6): 417–23. DOI: 10.4158/EP.8.6.417. PMID: 15251831.

24. Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.Gynecol Endocrinol. 2011 Apr; 27 (4): 256–62. DOI: 10.3109/09513590.2010.538099. Epub 2010 Dec 10. PMID: 21142777.

25. Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):537–40. PMID: 23467955.

26. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012 Dec; 28 (12): 969–73. DOI: 10.3109/09513590.2012.685205. Epub 2012 May 21. PMID: 22612517.

27. Dell’Edera D, Sarlo F, Allegretti A, Simone F, Lupo MG, Epifania AA. The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance. Biomed Rep. 2017 Aug; 7 (2): 169–172. DOI: 10.3892/br.2017.939. Epub 2017 Jul 4. PMID: 28804631.

28. Maurizi AR, Menduni M, Del Toro R, Kyanvash S, Maggi D, Guglielmi C, Pantano AL, Defeudis G, Fioriti E, Manfrini S, Pozzilli P. A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol. 2017 Apr; 54 (4): 361–365. DOI: 10.1007/s00592–016–0954-x. Epub 2016 Dec 30. PMID: 28039583.

29. Malvasi A, Casciaro F, Minervini MM, Kosmas I, Mynbaev OA, Pacella E, Monti Condesnitt V, Creanza A, Di Renzo GC, Tinelli A. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014; 18 (2): 270–4. PMID: 24488919.

30. Громова О.А., Торшин И.Ю., Гусев Е.И. Синергидные нейропротекторные эффекты тиамина, пиридоксина и цианокобаламина в рамках протеома человека. Фармакокинетика и Фармакодинамика. 2017; 1: 40–51.

31. Kato M, Wynn RM, Chuang JL, Tso SC, Machius M, Li J, Chuang DT. Structural basis for inactivation of the human pyruvate dehydrogenase complex by phosphorylation: role of disordered phosphorylation loops. Structure. 2008 Dec 10; 16 (12): 1849–59. DOI: 10.1016/j.str.2008.10.010. PMID: 19081061

32. Gao R, Liu Z, Meng M, Song X, He J. Neurogenesis-Associated Protein, a Potential Prognostic Biomarker in Anti-PD-1 Based Kidney Renal Clear Cell Carcinoma Patient Therapeutics. Pharmaceuticals (Basel). 2024 Mar 30; 17 (4): 451. DOI: 10.3390/ph17040451. PMID: 38675412.

33. Yen HW, Jakimiuk AJ, Munir I, Magoffin DA. Selective alterations in insulin receptor substrates-1,–2 and –4 in theca but not granulosa cells from polycystic ovaries. Mol Hum Reprod. 2004 Jul; 10 (7): 473–9. DOI: 10.1093/molehr/gah066. Epub 2004 May 21. PMID: 15155816.

34. Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009 Aug; 25 (8): 508–13. DOI: 10.1080/09513590903015544. PMID: 19551544.

35. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr; 13 (2): 105–10. PMID: 19499845.

36. Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, Di Benedetto A, D’Anna R. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. 2011 Jan; 18 (1): 102–4. DOI: 10.1097/gme.0b013e3181e8e1b1. PMID: 20811299.

37. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29; 340 (17): 1314–20. DOI: 10.1056/NEJM199904293401703. PMID: 10219066.

38. Papaleo E, Molgora M, Quaranta L, Pellegrino M, De Michele F. Myo-inositol products in polycystic ovary syndrome (PCOS) treatment: quality, labeling accuracy, and cost comparison. Eur Rev Med Pharmacol Sci. 2011 Feb; 15 (2): 165–74. PMID: 21434483.

39. Громова О.А., Торшин И.Ю. Микронутриенты и репродуктивное здоровье. Руководство. 2-е изд., перераб. и доп. ГЭОТАР-Медиа, 2022. 832 c. ISBN 978-5-9704-6786-2.

40. Petersen JM, Parker SE, Crider KS, Tinker SC, Mitchell AA, Werler MM. One-Carbon Cofactor Intake and Risk of Neural Tube Defects Among Women Who Meet Folic Acid Recommendations: A Multicenter Case-Control Study. Am J Epidemiol. 2019 Jun 1; 188 (6): 1136–1143. DOI: 10.1093/aje/kwz040. PMID: 30976786.

41. Min H, Lee M, Kang S, Shim YH. Vitamin B 12 Supplementation Improves Oocyte Development by Modulating Mitochondria and Yolk Protein in a Caffeine-Ingested Caenorhabditis elegans Model. Antioxidants (Basel). 2023 Dec 28; 13 (1): 53. DOI: 10.3390/antiox13010053. PMID: 38247478; PMCID: PMC 10812423.

42. Громова О. А., Лиманова О. А., Торшин И. Ю., Керимкулова Н. В., Рудаков К. В. Дозозависимость защитных эффектов фолиевой кислоты в прегравидарный период, во время беременности и в период лактации. РМЖ. Мать и дитя. 2014; 1: 27–34.

43. Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011 May; 15 (5): 509–14. PMID: 21744744.

44. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013 Apr; 29 (4): 375–9. DOI: 10.3109/09513590.2012.743020. Epub 2013 Jan 22. PMID: 23336594.

45. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Retraction Note: Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2023 Sep; 27 (18): 8323. DOI: 10.26355/eurrev_202309_33752. PMID: 37782148.

46. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):151–9. PMID: 15206484.

47. Venturella R, Mocciaro R, De Trana E, D’Alessandro P, Morelli M, Zullo F. Valutazione delle modificazioni del profilo clinico, endocrino e metabolico di pazienti con sindrome dell’ovaio policistico in trattamento con mio-inositolo [Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol]. Minerva Ginecol. 2012 Jun; 64 (3): 239–43. Italian. PMID: 22635019.

48. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011 Aug; 15 (8): 931–6. PMID: 21845803.

49. Громова О.А., Торшин И.Ю., Гришина Т.Р., Громов А.Н., Лиманова О.А. Систематический анализ молекулярно-физиологических эффектов миоинозитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия. 2013; 28: 4–12.

50. Tsuji A, Nakamura T, Shibata K. Effects of Mild and Severe Vitamin B1 Deficiencies on the Meiotic Maturation of Mice Oocytes. Nutr Metab Insights. 2017 Mar 15; 10: 1178638817693824. DOI: 10.1177/1178638817693824. PMID: 28469464; PMCID: PMC 5395269.

51. Mokhtari S, Mahdavi AH, Jafarpour F, Andani MR, Dattilo M, Nasr-Esfahani MH. Taurine, alpha lipoic acid and vitamin B6 ameliorate the reduced developmental competence of immature mouse oocytes exposed to methylglyoxal. Sci Rep. 2024 Aug 2; 14 (1): 17937. DOI: 10.1038/s41598-024-66785-5. PMID: 39095405; PMCID: PMC 11297043.

52. Lisi F, Carfagna P, Oliva MM, Rago R, Lisi R, Poverini R, Manna C, Vaquero E, Caserta D, Raparelli V, Marci R, Moscarini M. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol. 2012 Jul 23; 10: 52. DOI: 10.1186/1477-7827-10-52. PMID: 22823904; PMCID: PMC 3416732.

53. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011 Apr; 15 (4): 452–7. PMID: 21608442.

54. Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011 May; 15 (5): 509–14. PMID: 21744744.

55. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013 Dec; 288 (6): 1405–11. DOI: 10.1007/s00404‑013‑2855‑3. Epub 2013 May 25. PMID: 23708322.

56. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary.Fertil Steril. 2011 Jun 30; 95 (8): 2515–6. DOI: 10.1016/j.fertnstert.2011.05.027. Epub 2011 Jun 8. PMID: 21641593

57. Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab. 2018 Nov; 29 (11): 768–780. DOI: 10.1016/j.tem.2018.09.001. Epub 2018 Sep 27. PMID: 30270194.

58. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006 Feb; 29 (2): 300–5. DOI: 10.2337/diacare.29.02.06.dc05–1070. PMID: 16443877.

59. Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci. 2017 Dec; 21 (23): 5491–5498. DOI: 10.26355/eurrev_201712_13940. PMID: 29243796.

60. Cogram P, Tesh S, Tesh J, Wade A, Allan G, Greene ND, Copp AJ. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod. 2002 Sep; 17 (9): 2451–8. DOI: 10.1093/humrep/17.9.2451. PMID: 12202440.

61. Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014 Mar; 30 (3): 205–8. DOI: 10.3109/09513590.2013.860120. Epub 2013 Dec 19. PMID: 24351072.

62. Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019 Jun; 23 (12): 5512–5521. DOI: 10.26355/eurrev_201906_18223. PMID: 31298405.

63. Le Donne M, Metro D, Alibrandi A, Papa M, Benvenga S. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2019 Mar; 23 (5): 2293–2301. DOI: 10.26355/eurrev_201903_17278. PMID: 30915778.

64. Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, Laganà AS, Chan SY, Bevilacqua A, Pkhaladze L, Benvenga S, Stringaro A, Barbaro D, Appetecchia M, Aragona C, Bezerra Espinola MS, Cantelmi T, Cavalli P, Chiu TT, Copp AJ, D’Anna R, Dewailly D, Di Lorenzo C, Diamanti-Kandarakis E, Hernández Marín I, Hod M, Kamenov Z, Kandaraki E, Monastra G, Montanino Oliva M, Nestler JE, Nordio M, Ozay AC, Papalou O, Porcaro G, Prapas N, Roseff S, Vazquez-Levin M, Vucenik I, Wdowiak A. Inositols: From Established Knowledge to Novel Approaches. Int J Mol Sci. 2021 Sep 30; 22 (19): 10575. DOI: 10.3390/ijms221910575. PMID: 34638926; PMCID: PMC 8508595.

65. Carlomagno G, De Grazia S, Unfer V, Manna F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. 2012 Mar; 9 (3): 267–71. DOI: 10.1517/17425247.2012.662953. PMID: 22339497.